Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)

BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and reduced cardiovascular morbidity and mortality...

Descripción completa

Detalles Bibliográficos
Autores principales: Sudano, Isabella, Mach, Francois, Moccetti, Tiziano, Burkard, Thilo, Fahe, Christian, Delabays, Alain, Rickli, Hans, Keller, Pierre-Frédéric, Dopheide, Jörn, Bodenmann, Sereina, Fiolka, Tom, Ehret, Georg, Spirk, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335009/
https://www.ncbi.nlm.nih.gov/pubmed/35911507
http://dx.doi.org/10.3389/fcvm.2022.953040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335009/
https://www.ncbi.nlm.nih.gov/pubmed/35911507
http://dx.doi.org/10.3389/fcvm.2022.953040

Ejemplares similares